.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
US Department of Justice
Federal Trade Commission
QuintilesIMS
Moodys
Colorcon
Mallinckrodt
Cantor Fitzgerald
Fish and Richardson
Express Scripts

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Gene expression markers of tumor resistance to HER2 inhibitor treatment
Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
Inventor(s): Lee-Hoeflich; Si Tuen (Millbrae, CA), Stern; Howard (San Carlos, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:12/806,419
Patent Claims:1. A method of predicting the likelihood of response of a mammalian subject diagnosed with or at risk of developing a HER2 expressing tumor to treatment with a HER2 inhibitor, comprising (a) measuring in a tumor cell sample obtained from said human subject, an identical or increased expression level of the RNA transcript or expression product of a PPM1H gene relative to the expression level of PPM1H gene in a normal cell of the same cell type, wherein the identical or increased expression level identifies the subject as not likely to be resistant to treatment with trastuzumab, and (b) treating the subject with trastuzumab.

2. The method of claim 1 wherein the tumor is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophagael cancer, tumors of the biliary tract, and head and neck cancer.

3. The method of claim 1 wherein the tumor is selected from the group consisting of carcinomas of the stomach, endometrium, salivary gland, lung, kidney, colon, thyroid, pancreas and bladder, and prostate cancer.

4. The method of claim 1 wherein the tumor is breast cancer.

5. The method of claim 4 wherein the tumor is metastatic breast cancer.

6. The method of claim 1 wherein the tumor cell sample is from a fixed, wax-embedded cancer tissue specimen of said patient.

7. The method of claim 1 wherein the tumor cell sample is a core biopsy tissue.

8. The method of claim 1 wherein said tumor cell sample is from a biological fluid.

9. The method of claim 8 wherein the biological fluid is selected from the group consisting of blood, urine, saliva, ascites fluid, blood serum and blood plasma.

10. The method of claim 1, wherein measurement of the expression level is implemented using an apparatus adapted to determine the expression level of said RNA transcript or said expression products.

11. The method of claim 10, wherein the measurement of the expression levels is performed by using a software program executed by a suitable processor.

12. The method of claim 11, wherein the program is embodied in software stored on a tangible medium.

13. The method of claim 12, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

14. The method of any one of claims 10 to 13, further comprising the step of preparing a report recording the results of said measurement.

15. The method of claim 14, wherein said report is recorded or stored on a tangible medium.

16. The method of claim 15, wherein the tangible medium is paper.

17. The method of claim 15, wherein the tangible medium is selected from the group consisting of a CD-ROM, a floppy disk, a hard drive, a DVD, and a memory associated with the processor.

18. The method of any one of claims 10 to 17, further comprising the step of communicating the results of said determination to an interested party.

19. The method of claim 18, wherein the interested party is the patient or the attending physician.

20. The method of claim 18 or claim 19, wherein the communication is in writing, by email, or by telephone.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe Genentech, Inc. (South San Francisco, CA) Lee-Hoeflich; Si Tuen (Millbrae, CA), Stern; Howard (San Carlos, CA) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Canada2690334Dec 18, 2008
Canada2690334Feb 14, 2017
Canada2917355Dec 18, 2008
Denmark2171090Jun 10, 2013
European Patent Office2171090Apr 03, 2013
European Patent Office2171090Apr 07, 2010
European Patent Office2592156Apr 20, 2016
European Patent Office2592156Aug 14, 2013
European Patent Office2592156May 15, 2013
Spain2417148Aug 06, 2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Healthtrust
Queensland Health
Merck
McKinsey
Fish and Richardson
Accenture
Fuji
Teva
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot